Aduro BioTech secures $55 mln Series C
Clinical stage biotechnology company Aduro BioTech has closed a $55 million Series C financing. New investor Johnson & Johnson Development Corporation joined the Morningside group and other new and existing investors in the transaction.
12 June 2014•4 mins read
